KCM
KRTX

KRS Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

KRS Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,364
Closed -$748K – 122
2023
Q4 		$748K Buy
2,364
+450
+24% +$87.5K 0.7% 36
2023
Q3 		$324K Buy
1,914
+205
+12% +$38.5K 0.34% 76
2023
Q2 		$371K Buy
1,709
+25
+1% +$5.36K 0.37% 74
2023
Q1 		$306K Buy
+1,684
New +$322K 0.34% 85
2022
Q1 		– Sell
-300
Closed -$39K – 387
2021
Q4 		$39K Buy
+300
New +$38.8K 0.03% 244

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

KRS Capital Management's KRTX Position: Q1 2024 in Review

KRS Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 2,364 shares — an estimated $748K sold.

KRS Capital Management first reported a position in KRTX in Q4 2021 and held it in 5 quarters. The position peaked at $748K in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • KRS Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • KRS Capital Management sold 2,364 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $748K.
  • KRS Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
  • KRS Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $748K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on KRS Capital Management's 13F filing for Q1 2024, filed 16 Apr 2024.